Lilly Cancer Drug Shouldn't Be Started in New Patients, FDA Says

(Bloomberg) -- Eli Lilly & Co.’s cancer drug Lartruvo shouldn’t be started in new patients and those already taking it should ask their doctors if they should continue, U.S. regulators said, follow...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.